David Lennon, who heads Novartis' Zolgensma development programme, expressed confidence that the drugmaker has sufficient production capacity to meet demand for the therapy, as reported NASDAQ Wednesday.
Novartis expects the drug to be approved by the FDA this month.
Meanwhile, Lennon dismissed media reports that Novartis would price the drug at $2 million as "complete speculation."
Novartis, which acquired Zolgensma via its $8.7-billion takeover of AveXis last year, previously indicated that the treatment could be priced at $1.5 million to $5 million per patient.
To read more NewsPoints articles, click here.